Peer-Reviewed Data Underscore Lenire Outcomes in U.S. Tinnitus Patients

According to a recent LinkedIn post from Neuromod Devices Ltd, an analysis of real-world U.S. tinnitus patients treated with its Lenire device has been profiled by MassDevice. The post cites a paper by Dr. Craig Kasper, published in ASHA Journals, reporting that 81.8% of 140 patients experienced tinnitus relief and showed a mean reduction of 23.8 points on the THI scale.

The LinkedIn post notes that these outcomes appear consistent with a prior real-world analysis of U.S. Lenire patients published in a Nature Portfolio journal. For investors, the emergence of independent, peer-reviewed data supporting Lenire’s effectiveness could strengthen Neuromod Devices’ clinical credibility, potentially aiding physician adoption, reimbursement discussions, and long-term revenue prospects in the tinnitus and broader hearing-care markets.